New US Medicare guidelines could affect Novo Nordisk's Wegovy
”Being concerned over Novo risking lower prices is fair,” says one analyst, pointing out that proposed rules might still change.
by marketwire, translated by daniel pedersen
The US Government’s new rules for public healthcare insurance seeks to group medicines based on the same active ingredients when negotiating prices with drugmakers.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Wegovy exponents did not disclose payments from Novo Nordisk
For subscribers
.jpg&w=384&q=75)
